Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma.

NCT00350597 is registered in ClinicalTrials.gov with Northern California Melanoma Center as lead sponsor.

NCT NCT00350597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00350597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma.
Lead sponsor
Northern California Melanoma Center
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
July 31, 2010
Enrollment
50
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma